Biomarkers may help ID patients at increased risk of neurotoxicity from CD19 CAR T-cell therapyOctober 12, 2017
Bottom Line: New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.
Journal in Which the Study was Published: Cancer Discovery, a journal of the American Association for Cancer Research.
Authors: Cameron J. Turtle, MBBS, PhD, associate member at Fred Hutchinson Cancer Research Center, associate professor at the University of Washington, and attending physician on the Immunotherapy Service at Fred Hutch.
Background: On August 30, 2017, the FDA approved the first CD19 CAR T-cell therapy, tisagenlecleucel (Kymriah), for the treatment of acute lymphoblastic leukemia (ALL) in certain pediatric and young adult patients. Different CD19 CAR T-cell therapies are being developed and tested, and reports show that a small number of patients who received certain forms of this therapy in clinical trials have died from severe neurotoxicity.
Turtle and colleagues sought to provide a detailed clinical, radiological, and pathological characterization of neurotoxicity arising from CD19 CAR T-cell therapy.
How the Study Was Conducted: The researchers used data from a clinical trial in which 133 adult patients with relapsed and/or refractory CD19 B-cell ALL, non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated with lymphodepletion chemotherapy followed by infusion of JCAR014, a type of CD19 CAR T-cell therapy developed at Fred Hutchinson Cancer Research Center.
Within 28 days of treatment, 53 patients (40 percent) developed grade 1 or higher neurologic adverse events and of these 28 (21 percent) had grade 3 or higher neurotoxicity; alterations in neurologic status completely resolved in a majority of cases. Four of the 133 patients (3 percent) developed fatal neurotoxicity.
Results: Turtle and colleagues found that patients with an early onset of CRS were at increased risk of subsequently developing severe neurotoxicity. While tocilizumab (Actemra), an IL-6R antagonist approved by the FDA to treat CRS, was effective in ameliorating CRS-related fever and hypotension in most patients, the team found that its role in preventing or treating neurotoxicity is less clear.
Patients who experienced neurotoxicity were mostly younger and had B-cell ALL, higher tumor burden, and more CD19-positive cells in the bone marrow, compared with those who did not develop this side effect. Data also revealed that those with severe neurotoxicity had endothelial activation, which could contribute to manifestations such as capillary leak, blood coagulation abnormalities, and disruption of the blood-brain barrier that were observed in patients with severe CRS and neurotoxicity.
Turtle and colleagues developed a predictive classification tree algorithm based on the side effects, including fever, and high serum IL-6 and MCP-1, to identify patients, within the first 36 hours after CAR T-cell infusion, who are at increased risk for severe neurotoxicity. Patients at increased risk for this adverse event may benefit from early intervention, Turtle noted; however, he pointed out that additional studies are required.
Authors' Comments: "CD19 CAR T-cell therapy is a highly effective, novel treatment modality that has rapidly expanded in the cancer research and treatment field over the past few years, including recent approval of one form of this therapy by the U.S. Food and Drug Administration [FDA]," said Turtle.
"There is understandably anxiety about some of the side effects of CD19 CAR T-cell therapy, but these treatments have been very effective for a subgroup of patients with resistant disease," he said. "It is important to understand the side effects, such as cytokine release syndrome [CRS] and neurological toxicity."
Enormous improvements have been made in the last few years in strategies to minimize the risk of toxicity, Turtle noted. "Because CAR T-cell therapy is so new, we are still learning how to improve the delivery and reduce the side effects," he added.
Limitations: Limitations of the study include that the characterization of side effects was only from patients who received JCAR014 and not other forms of CD19 CAR T-cell therapies, Turtle said.
Fred Hutch, where Turtle and other co-authors are employed, has a financial interest in Juno, and receives licensing and other payments from the company.
To interview Cameron Turtle, contact Julia Gunther at email@example.com or 215-446-6896.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
American Association for Cancer Research
Related Cancer Research Articles:
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.
CANCER RESEARCH UK has tripled its investment in pancreatic cancer, one of the hardest cancers to treat, since launching its research strategy in 2014 according to new figures published today (Wednesday).
Dr. Hao Zhu, Assistant Professor of Children's Medical Center Research Institute at UT Southwestern, is one of 10 researchers in the nation to receive a Stand Up to Cancer grant to further his studies of a gene whose absence protects mice against liver cancer and promotes liver tissue regeneration in mammals.
Drug-carrying 'nanoghosts' that battle melanoma and new treatments for malignant mesothelioma will be the focus of the first joint research projects led by NYU Langone Medical Center and the Technion-Israel Institute of Technology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
A study by researchers at Marshall University Joan C. Edwards School of Medicine has found that blocking the blood supply of small cell lung cancer tumors may help reduce their growth and delay the regrowth process after treatment.
Related Cancer Research Reading:
Cancer Research Secrets: Therapies which work and those which don't
by Keith Scott-Mumby (Author), Dragos Balasoiu (Designer)
A comprehensive report on a wide range of cancer alternative treatments that have been shown to work. These are not always alternatives to orthodox treatments but can run in parallel. The author is an internationally-known MD with knowledge and experience of a wide range of holistic therapies. View Details
The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable--and How We Can Get There
by Vincent T. DeVita Jr. M.D. (Author), Elizabeth DeVita-Raeburn (Author)
The true story of the war on cancer from one of its generals
Cancer touches everybody's life in one way or another. But most of us know very little about how the disease works, why we treat it the way we do, and the personalities whose dedication got us where we are today. For fifty years, Dr. Vincent T. DeVita Jr. has been one of those key players: He has held just about every major position in the field, and he developed the first successful chemotherapy treatment for Hodgkin's lymphoma. As one of oncology's leading figures, DeVita knows what cancer looks like from the lab... View Details
The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)
Winner of the Pulitzer Prize, and now a documentary from Ken Burns on PBS, The Emperor of All Maladies is a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence.
Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly... View Details
Essential Oil Cancer Research
by Nicole Stevens (Author)
Follow scientist Nicole Stevens as she studies over 60 different essential oils to discover which might hold the key to curing cancer! This full-color booklet explores what cancer is and why it is so difficult to treat, and presents the results of Nicole's amazing study, as well as additional research that has been done on several different essential oils. Contents What is Cancer? Challenges with Cancer Diagnosis Challenges with Current Cancer Treatments Plants as Medicine Essential Oil Screening Study Study Results Other Essential Oil Cancer Research Conclusions Glossary of Terms References View Details
Targeted Therapy in Translational Cancer Research (Translational Oncology)
by Apostolia-Maria Tsimberidou (Editor), Razelle Kurzrock (Editor), Kenneth C. Anderson (Editor), Robert C. Bast Jr. (Editor), Maurie Markman (Editor), Ernest Hawk (Editor)
Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy.
Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of... View Details
The Immortal Life of Henrietta Lacks
by Rebecca Skloot (Author)
Now an HBO® Film starring Oprah Winfrey and Rose Byrne
#1 NEW YORK TIMES BESTSELLER
Her name was Henrietta Lacks, but scientists know her as HeLa. She was a poor black tobacco farmer whose cells—taken without her knowledge in 1951—became one of the most important tools in medicine, vital for developing the polio vaccine, cloning, gene mapping, and more. Henrietta's cells have been bought and sold by the billions, yet she remains virtually unknown, and her family can't afford health insurance. This phenomenal New York Times bestseller tells a riveting story... View Details
Cancer research and prevention
by United States Congress (Author), United States Senate (Author), Committee on Appropriations (Author)
Cancer research and prevention : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Seventh Congress, second session, special hearing, June 4, 2002, Washington, DC. View Details
Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective.
by World Cancer Research Fund / American Institute for Cancer Research (Author)
The Second Expert Report, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective offers the most up-to-date recommendations for individuals and populations. They are based on the conclusions of an expert panel that certain foods, drinks and lifestyle choices protect against or lead to the development of one or more types of cancer. Additionally, the report explains how the panel reached its conclusions and what those conclusions mean to researchers, educators, practitioners and policymakers around the world. It is the largest report of its kind ever... View Details
2: Statistical Methods in Cancer Research (IARC Scientific Publications)
by N.E. Breslow (Author), N.E. Day (Author)
Together with Volume I, this work provides a comprehensive account of the major types of studies in cancer epidemiology. Its scope ranges from an account of elementary and descriptive cohort analyses to the fitting of regression models for incidence rates with general risk functions. Particular attention is given to the use of a case-control approach embedded in a cohort study. As in the first volume, all methods are illustrated by examples from real studies, and the data are appended to the text, enabling readers to rework the computations. View Details
Eat To Beat Cancer: A Research Scientist Explains How You and Your Family Can Avoid Up to 90% of All Cancers
by J. Robert Hatherill Ph.D. (Author)
If changing what you eat could keep you from getting cancer, wouldn't you do it?
Dr. Hatherill's Super Eight Food Groups are the foundation of a strategy that will help you create a cancer-busting regimen for yourself and your family. In this courageous book, Hatherill takes on the pharmaceutical and food industries to disclose dangers inherent in common foods like dairy and meat products, as well as over-the-counter supplements.
"In...humbler times people rarely got cancer...Heart disease was so rare that medical textbooks from the mid-to late 1800s failed to... View Details